Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Trial Profile

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Droxidopa (Primary) ; Carbidopa
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Apr 2018 Planned End Date changed from 17 Apr 2018 to 1 Aug 2018.
    • 24 Apr 2018 Planned primary completion date changed from 17 Apr 2018 to 1 Aug 2018.
    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top